FY2026 · ended Jun 30, 2026 · Revenue $1.17M, -92.5% YoY · Filed Sep 18, 2026
Neuphoria Therapeutics Inc. (NEUP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $1.2 million and a net loss of $13.5 million.
Revenue
$1.17M
-92.5% vs prior year
Net income
$-13.45M
-3539.3% vs prior year
Operating cash flow
$-12.35M
-16095.4% vs prior year
Free cash flow
—
EPS
$-3.06
-1230.4% vs prior year
Dividend per share
None
Shares outstanding
5.41M
+129.5% vs prior year
Net cash
$14.09M
FY 2025
Operating margin
-1401.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NEUP (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Burlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1191070
- Former names
- BIONOMICS LIMITED/FI (until Dec 23, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
|---|---|---|---|
| Revenue | $1.2M | $15.6M | — |
| Operating income | -$16.5M | -$1.1M | -$17.9M |
| Net income | -$13.5M | -$369,632 | -$15.5M |
| Diluted EPS | -$3.06 | -$0.23 | -$18.62 |
| Operating cash flow | -$12.4M | $77,229 | -$14.7M |
| Total assets | $28.7M | $28.6M | $27.6M |
| Total liabilities | $4.1M | $9.6M | $10.2M |
| Stockholders' equity | $24.6M | $19.0M | $17.5M |
| Cash and investments | $19.9M | $14.2M | $12.6M |
| Total debt | — | $116,314 | $239,618 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Oct 23, 2026 | Oct 23, 2026 |
| 10-K | Annual report | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change in control, Regulation FD disclosure
|
Jul 24, 2026 | Jul 20, 2026 |
| 8-K |
Current report
Other events
|
May 26, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
All 420 Neuphoria Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.